Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
PRO-1184 by Genmab for Endometrial Cancer: Likelihood of Approval
PRO-1184 is under clinical development by Genmab and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase II...
PRO-1184 by Genmab for Non-Small Cell Lung Cancer: Likelihood of Approval
PRO-1184 is under clinical development by Genmab and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData,...
PRO-1184 by Genmab for Fallopian Tube Cancer: Likelihood of Approval
PRO-1184 is under clinical development by Genmab and currently in Phase II for Fallopian Tube Cancer. According to GlobalData, Phase...
PRO-1184 by Genmab for Malignant Mesothelioma: Likelihood of Approval
PRO-1184 is under clinical development by Genmab and currently in Phase II for Malignant Mesothelioma. According to GlobalData, Phase II...
PRO-1184 by Genmab for Peritoneal Cancer: Likelihood of Approval
PRO-1184 is under clinical development by Genmab and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase II...
PRO-1184 by Genmab for Epithelial Ovarian Cancer: Likelihood of Approval
PRO-1184 is under clinical development by Genmab and currently in Phase II for Epithelial Ovarian Cancer. According to GlobalData, Phase...
PRO-1184 by Genmab for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
PRO-1184 is under clinical development by Genmab and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Negative...
PRO-1184 by Genmab for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
PRO-1184 is under clinical development by Genmab and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData,...
PRO-1184 by ProfoundBio Suzhou for Peritoneal Cancer: Likelihood of Approval
PRO-1184 is under clinical development by ProfoundBio Suzhou and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase...
PRO-1184 by ProfoundBio Suzhou for Fallopian Tube Cancer: Likelihood of Approval
PRO-1184 is under clinical development by ProfoundBio Suzhou and currently in Phase II for Fallopian Tube Cancer. According to GlobalData,...